Notch pathway signaling inhibitor compound
AssigneeEli Lilly and Company
InventorsPhilip Arthur Hipskind, Gregory Alan Stephenson
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.
Claims6
A compound of the structure:
- or a pharmaceutically acceptable salt or hydrate thereof.
A crystalline hydrate of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide characterized by an X-ray powder diffraction pattern using CuKα radiation having a peak at 22.97±0.2 degrees 2-theta in combination with one or more peaks at 11.96±0.2, 18.81±0.2, 20.78±0.2 or 21.07±0.2 degrees 2-theta at ambient temperature and relative humidity.
Dependencies are inferred from the claim text.